Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
RLAY
RLAY
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
RLAY News
Relay Therapeutics Executive Large Share Sale Analysis
Feb 06 2026
Fool
Oncolytics Biotech Receives FDA Fast Track Designation
Feb 05 2026
PRnewswire
FDA Accelerates Oncology Drug Approvals, Boosting Market Potential
Feb 05 2026
Newsfilter
Relay Therapeutics Receives FDA Breakthrough Therapy Designation
Feb 03 2026
Newsfilter
Oppenheimer Upgrades Relay Therapeutics Rating
Jan 26 2026
seekingalpha
Oncolytics Biotech Secures FDA Approval with 33% Efficacy for New Drug
Dec 16 2025
Newsfilter
Oncolytics Biotech Secures FDA Approval with 33% Efficacy for Pelareorep in Colorectal Cancer
Dec 16 2025
Globenewswire
Relay Therapeutics Announces Strong Efficacy of Targeted Breast Cancer Treatment
Dec 12 2025
Benzinga
Relay Therapeutics Reports zovegalisib Clinical Data with 10.3-Month PFS
Dec 12 2025
Globenewswire
Relay Therapeutics Reports zovegalisib Clinical Data with 10.3-Month PFS
Dec 12 2025
Newsfilter
Relay Therapeutics Shares Surge 60% Over the Past Year as an Investor Acquires Nearly 4 Million Additional Shares
Dec 03 2025
NASDAQ.COM
Major Stocks Including Alibaba, Oscar Health, Ondas Holdings, Lumentum, and Tesla Rise on Monday
Nov 24 2025
Benzinga
Purchase Relay Therapeutics for $5 and Achieve 22.4% Annualized Returns Through Options
Nov 18 2025
NASDAQ.COM
Medtronic Set for Potential 25% Surge? Check Out 10 Leading Analyst Predictions for Tuesday
Aug 26 2025
Benzinga
Relay Therapeutics (RLAY) Upgraded to Buy: What Does It Mean for the Stock?
Aug 12 2025
NASDAQ.COM
Relay (RLAY) Q2 Loss Narrows 41%
Aug 07 2025
NASDAQ.COM
Show More News
